SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-049099
Filing Date
2024-04-26
Accepted
2024-04-26 16:06:56
Documents
17
Period of Report
2024-04-26

Document Format Files

Seq Description Document Type Size
1 DEF 14A kzr-20240426.htm   iXBRL DEF 14A 1155778
2 GRAPHIC img40157682_0.jpg GRAPHIC 27865
3 GRAPHIC img40157682_1.jpg GRAPHIC 214302
4 GRAPHIC img40157682_2.jpg GRAPHIC 207398
5 GRAPHIC img40157682_3.jpg GRAPHIC 850925
6 GRAPHIC img40157682_4.jpg GRAPHIC 173049
  Complete submission text file 0000950170-24-049099.txt   5149965

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kzr-20240426.xsd EX-101.SCH 38779
20 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20240426_htm.xml XML 219246
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38542 | Film No.: 24883635
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)